

**Contact:**

Jarrold Longcor  
Senior Director Business Development  
MaxCyte, Inc.  
(301) 944-1700

**For Immediate Release**

***MaxCyte Organizes Stem Cell Session at BIO 2007***

*“Delivering the Promise of Stem Cell Therapeutics”*

**Gaithersburg, MD, May 3, 2007** – MaxCyte, Inc., a clinical stage therapeutics company and pioneer in cell loading systems, announces a panel session on stem cell therapeutics entitled, “Delivering the Promise of Stem Cell Therapeutics?” will take place at BIO 2007 - the Biotechnology Industry Organization’s annual meeting and convention. The meeting is being held May 6–10, 2007 in Boston, Massachusetts. Scheduled for 9:15 a.m., Monday, May 7, 2007, the session will evaluate the current state of stem cell therapies and the potential for engineering stem cells as a method of developing better, more potent therapies. The session will include a discussion of the regulatory issues surrounding existing and engineered stem cell therapies, as well as specific company initiatives in the development of stem cell-based therapeutics.

Madhusudan Peshwa, Ph.D., Vice President of Research & Development at MaxCyte will be joined on the panel by Marc Hedrick, M.D. President of Cytori Therapeutics, Duncan Stewart, M.D. Director of Cardiology at the University of Toronto, James Kenimer, Ph.D. President of Biologics Consulting Group, and Garheng Kong, M.D., Ph.D., of Intersouth Partners, who will moderate.

**About MaxCyte**

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary *ex vivo* cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.

**Madhusudan Peshwa, Ph.D.**

Madhusudan V. Peshwa, Ph.D., currently serves as Vice President, Research and Development at MaxCyte, Inc. Dr. Peshwa obtained his Ph.D. in Chemical Engineering from the University of

Minnesota and his B.Tech. in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 35 scientific publications and is a co-inventor on five, issued or under review, patent applications. Dr. Peshwa currently serves on the Scientific Advisory Board for the BioProcess Engineering Center at MIT and Immune Cell Therapy, a private biotechnology company.

**For more information, visit <http://www.maxcyte.com>.**

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###